{"words": ["study", "association", "time", "therapeutic", "range", "ttr", "warfarin", "therapy", "risk", "dementia", "cohort", "incident", "atrial", "fibrillation", "af", "conducted", "observational", "study", "2800", "nondemented", "patients", "incident", "af", "january", "1", "2000", "december", "31", "2010", "association", "incident", "dementia", "warfarin", "therapy", "ttr", "examined", "using", "cox", "proportional", "hazards", "regression", "patient", "age", "years", "53", "men", "warfarin", "prescribed", "within", "90", "days", "af", "diagnosis", "incident", "dementia", "diagnosis", "occurred", "357", "patients", "mean", "sd", "years", "adjusting", "confounders", "warfarin", "therapy", "associated", "reduced", "incidence", "dementia", "hazard", "ratio", "hr", "95", "ci", "however", "2", "highest", "quartiles", "ttr", "associated", "lower", "risk", "dementia", "10", "increase", "ttr", "10", "reduction", "time", "spent", "subtherapeutic", "hr", "95", "ci", "supratherapeutic", "hr", "95", "ci", "ranges", "associated", "decreased", "risk", "community", "warfarin", "therapy", "af", "associated", "20", "reduction", "risk", "dementia", "increasing", "ttr", "warfarin", "associated", "reduced", "risk", "dementia", "risk", "dementia", "reduced", "reduction", "time", "spent", "subtherapeutic", "supratherapeutic", "international", "normalized", "ratio", "range", "effective", "anticoagulation", "may", "prevent", "cognitive", "impairment", "patients", "af"], "authors": [["Madhavan", "Malini", "M", "Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN. Electronic address: madhavan.malini@mayo.edu."], ["Hu", "Tiffany Y", "TY", "Department of Medicine, University of California, Los Angeles."], ["Gersh", "Bernard J", "BJ", "Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN."], ["Roger", "Veronique L", "VL", "Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN; Department of Health Sciences Research, Mayo Clinic, Rochester, MN."], ["Killian", "Jill", "J", "Department of Health Sciences Research, Mayo Clinic, Rochester, MN."], ["Weston", "Susan A", "SA", "Department of Health Sciences Research, Mayo Clinic, Rochester, MN."], ["Graff-Radford", "Jonathan", "J", "Department of Neurology, Mayo Clinic, Rochester, MN."], ["Asirvatham", "Samuel J", "SJ", "Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN."], ["Chamberlain", "Alanna M", "AM", "Department of Health Sciences Research, Mayo Clinic, Rochester, MN."]], "title": "Efficacy of Warfarin Anticoagulation and Incident Dementia in a Community-Based Cohort of Atrial Fibrillation.", "year": null, "sentences": ["To study the association between time in therapeutic range (TTR) during warfarin therapy and risk of dementia in a population-based cohort of incident atrial fibrillation (AF).We conducted an observational population-based study of 2800 nondemented patients with incident AF from January 1, 2000, through December 31, 2010.", "The association of incident dementia with warfarin therapy and TTR was examined using Cox proportional hazards regression models.Mean patient age was 71.2 years; 53% were men (n=1495), and warfarin was prescribed to 50.5% (n=1414) within 90 days of AF diagnosis.", "Incident dementia diagnosis occurred in 357 patients (12.8%) over a mean \u00b1 SD follow-up of 5.0\u00b13.7 years.", "After adjusting for confounders, warfarin therapy was associated with a reduced incidence of dementia (hazard ratio [HR], 0.80; 95% CI, 0.64-0.99).", "However, only those in the 2 highest quartiles of TTR were associated with lower risk of dementia.", "A 10% increase in TTR with a 10% reduction in time spent in the subtherapeutic (HR, 0.71; 95% CI, 0.64-0.79) and supratherapeutic (HR, 0.67; 95% CI, 0.57-0.79) ranges were associated with decreased risk of dementia.In the community, warfarin therapy for AF is associated with a 20% reduction in risk of dementia.", "Increasing TTR on warfarin is associated with reduced risk of dementia.", "The risk of dementia was reduced with a reduction in time spent in subtherapeutic and supratherapeutic international normalized ratio range.", "Effective anticoagulation may prevent cognitive impairment in patients with AF."], "id": "29329798", "text": "To study the association between time in therapeutic range (TTR) during warfarin therapy and risk of dementia in a population-based cohort of incident atrial fibrillation (AF).We conducted an observational population-based study of 2800 nondemented patients with incident AF from January 1, 2000, through December 31, 2010. The association of incident dementia with warfarin therapy and TTR was examined using Cox proportional hazards regression models.Mean patient age was 71.2 years; 53% were men (n=1495), and warfarin was prescribed to 50.5% (n=1414) within 90 days of AF diagnosis. Incident dementia diagnosis occurred in 357 patients (12.8%) over a mean \u00b1 SD follow-up of 5.0\u00b13.7 years. After adjusting for confounders, warfarin therapy was associated with a reduced incidence of dementia (hazard ratio [HR], 0.80; 95% CI, 0.64-0.99). However, only those in the 2 highest quartiles of TTR were associated with lower risk of dementia. A 10% increase in TTR with a 10% reduction in time spent in the subtherapeutic (HR, 0.71; 95% CI, 0.64-0.79) and supratherapeutic (HR, 0.67; 95% CI, 0.57-0.79) ranges were associated with decreased risk of dementia.In the community, warfarin therapy for AF is associated with a 20% reduction in risk of dementia. Increasing TTR on warfarin is associated with reduced risk of dementia. The risk of dementia was reduced with a reduction in time spent in subtherapeutic and supratherapeutic international normalized ratio range. Effective anticoagulation may prevent cognitive impairment in patients with AF.", "doi": "10.1016/j.mayocp.2017.09.021", "journal": ["Mayo Clinic proceedings", "Mayo Clin. Proc."], "date": "2018-01-18_23:40:48"}